Review
doi: 10.1158/1078-0432.CCR-06-2650.
Idiotype vaccination strategies in myeloma: how to overcome a dysfunctional immune system
Affiliations
- PMID: 17332275
- DOI: 10.1158/1078-0432.CCR-06-2650
Item in Clipboard
Review
Idiotype vaccination strategies in myeloma: how to overcome a dysfunctional immune system
Clin Cancer Res.
.
No abstract available
Comment on
-
Long-term idiotype vaccination combined with interleukin-12 (IL-12), or IL-12 and granulocyte macrophage colony-stimulating factor, in early-stage multiple myeloma patients.Clin Cancer Res. 2007 Mar 1;13(5):1503-10. doi: 10.1158/1078-0432.CCR-06-1603. Clin Cancer Res. 2007. PMID: 17332295 Clinical Trial.
Similar articles
-
Long-term idiotype vaccination combined with interleukin-12 (IL-12), or IL-12 and granulocyte macrophage colony-stimulating factor, in early-stage multiple myeloma patients.Clin Cancer Res. 2007 Mar 1;13(5):1503-10. doi: 10.1158/1078-0432.CCR-06-1603. Clin Cancer Res. 2007. PMID: 17332295 Clinical Trial.
-
Immunotherapy in multiple myeloma: current strategies and future prospects.Expert Rev Vaccines. 2003 Jun;2(3):391-8. doi: 10.1586/14760584.2.3.391. Expert Rev Vaccines. 2003. PMID: 12903804 Review.
-
Induction of cellular immune responses in patients with stage-I multiple myeloma after vaccination with autologous idiotype-pulsed dendritic cells.J Immunother. 2011 Jan;34(1):100-6. doi: 10.1097/CJI.0b013e3181facf48. J Immunother. 2011. PMID: 21150718 Clinical Trial.
-
Idiotypic vaccination as therapy for multiple myeloma.Semin Hematol. 1999 Jan;36(1 Suppl 3):34-7. Semin Hematol. 1999. PMID: 9989488 Review.
-
Idiotype-specific immunotherapy in multiple myeloma: suggestions for future directions of research.Haematologica. 2006 Jul;91(7):941-8. Haematologica. 2006. PMID: 16818282 Review.
Cited by
-
Neoantigen vaccine-induced CD4 T cells confer protective immunity in a mouse model of multiple myeloma through activation of CD8 T cells against non-vaccine, tumor-associated antigens.J Immunother Cancer. 2022 Feb;10(2):e003572. doi: 10.1136/jitc-2021-003572. J Immunother Cancer. 2022. PMID: 35190376 Free PMC article.
-
Trial watch: Dendritic cell-based interventions for cancer therapy.Oncoimmunology. 2012 Oct 1;1(7):1111-1134. doi: 10.4161/onci.21494. Oncoimmunology. 2012. PMID: 23170259 Free PMC article.
-
PD-L1-specific T cells.Cancer Immunol Immunother. 2016 Jul;65(7):797-804. doi: 10.1007/s00262-015-1783-4. Epub 2016 Jan 2. Cancer Immunol Immunother. 2016. PMID: 26724936 Free PMC article. Review.
-
The inhibitory checkpoint, PD-L2, is a target for effector T cells: Novel possibilities for immune therapy.Oncoimmunology. 2017 Nov 1;7(2):e1390641. doi: 10.1080/2162402X.2017.1390641. eCollection 2018. Oncoimmunology. 2017. PMID: 29308318 Free PMC article.
-
Boosting Immunity against Multiple Myeloma.Cancers (Basel). 2021 Mar 11;13(6):1221. doi: 10.3390/cancers13061221. Cancers (Basel). 2021. PMID: 33799565 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
